Leiomyosarcoma of the breast

Leiomyosarcoma of the breast: A case report and review of the literature about therapeutic management. The Breast, Oct 2011, Vol 20(5), p.389-393

Fujita, N., et al.


A leiomyosarcoma of the breast in an 18-year-old female. No specific treatment has been established. In order to clarify appropriate therapeutic management methods, the limited data available from our and previous case reports were assessed. A leiomyosarcoma of the breast must be excised with a negative margin. If the tumor size is large and an adequate margin, greater than 3-cm margin around the excised tumor, is not achieved due to anatomical constraints, radiotherapy may be indicated.

Reduction mammaplasty, obesity and massive weight loss

Reduction mammaplasty, obesity and massive weight loss: Temporal relationships of satisfaction with breast contour. Plastic and reconstructive surgery, Sept 2011, vol. 128(3), p. 643-650.

Coriddi, M., et al.

http://journals.lww.com/plasreconsurg/Fulltext/2011/09000/Reduction_Mammaplasty,_Obesity,_and_Massive_Weight.3.aspx

Reduction mammaplasty is often performed on obese women. With the rise in bariatric procedures, secondary changes to breast contour are increasing. This study aims to investigate the temporal relationships of breast contour satisfaction with weight status.

Anaplastic large cell lymphoma and breast implants

Anaplastic large cell lymphoma and breast implants: Results from a structured expert consultation process. Plastic and reconstructive surgery, Sept 2011, vol. 128(3), p. 629-639.

Kim, B., et al.

http://journals.lww.com/plasreconsurg/Fulltext/2011/09000/Anaplastic_Large_Cell_Lymphoma_and_Breast.1.aspx

There are increasing concerns about a possible association between anaplastic large cell lymphoma (ALCL) and breast implants. The authors conducted a structured expert consultation process to evaluate the evidence for the association, its clinical significance, and a potential biological model based on their interpretation of the published evidence.

A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast

A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast. Plastic and reconstructive surgery, Sept 2011, vol. 128(3), p. 112e-118e.

Carty, MJ, et al.

http://journals.lww.com/plasreconsurg/Fulltext/2011/09000/A_Patient_Death_Attributable_to_Implant_Related.5.aspx

Implant-related primary anaplastic large cell lymphoma (ALCL) of the breast is a rare clinical entity. With increasing attention being paid to this disease, most cases reported to date in the literature have demonstrated indolent clinical courses responsive to explantation, capsulectomy, chemotherapy, and/or radiotherapy. The authors describe a case of bilateral implant-related primary ALCL of the breast that proved refractory to both standard and aggressive interventions, ultimately resulting in patient death secondary to disease progression. The authors situate this case in the context of the current state of knowledge regarding implant-related primary ALCL of the breast and suggest that this entity is generally, but not universally, indolent in nature.

Anaplastic large T-cell lymphoma and breast implants

Anaplastic large T-cell lymphoma and breast implants: A review of the literature. Plastic and reconstructive surgery, Sept 2011, vol. 128(3), p. 651-661.

Jewell, M., et al.

http://journals.lww.com/plasreconsurg/Abstract/2011/09000/Anaplastic_Large_T_Cell_Lymphoma_and_Breast.4.aspx

Anecdotal reports and one case-control study suggested an association, without evidence of causation, between breast implants and anaplastic lymphoma kinase–negative anaplastic large T-cell lymphoma (ALCL), a rare non-Hodgkin's lymphoma. This review summarizes the published evidence, including case reports and epidemiologic studies.

Extending the age range for breast screening in England

Extending the age range for breast screening in England: pilot study to assess the feasibility and acceptability of randomization. Journal of medical screening, June 2011, vol. 18(2), p. 96-102.

Moser, K., et al.

http://jms.rsmjournals.com/content/18/2/96.short?rss=1

To assess the feasibility and acceptability of randomizing the phased introduction of the extension of the invited age range in the National Health Service (NHS) Breast Screening Programme in England from 50–70 to 47–73 years.

Screening outcomes in women over age 70 who self-refer in the NHSBSP in England

Screening outcomes in women over age 70 who self-refer in the NHSBSP in England. Journal of medical screening, June 2011, vol. 18(2), p. 291-295.

Bennett, RL, Moss, SM.

http://jms.rsmjournals.com/content/18/2/91.short?rss=1

The NHS breast screening programme (NHSBSP) in England currently invites women aged 50–70 every three years. Whilst screening is acknowledged as efficacious for women aged 50–69, several countries routinely invite women up to the age of 74. The NHSBSP in England is beginning to invite women up to the age of 73. Although the incidence of breast cancer increases with age, the possible benefits of screening older women must be balanced against shorter life expectancies and possible overdiagnosis. In England women can self-refer after reaching the invitation upper age limit.

Breast surface radiation dose during coronary CT angiography

Breast surface radiation dose during coronary CT angiography: Reduction by breast displacement and lead shielding. AJR, August 2011, vol. 197(2), p. 367-373.

Foley, SJ, et al.

http://www.ajronline.org/content/197/2/367.abstract?rss=1

The purpose of this study was to prospectively evaluate the effect of cranial breast displacement and lead shielding on in vivo breast surface radiation dose in women undergoing coronary CT angiography.

Microcalcifications around a collegen-based breast biopsy marker: complication of biopsy with a percutaneous marking system

Microcalcifications around a collegen-based breast biopsy marker: complication of biopsy with a percutaneous marking system. AJR, August 2011, vol. 197(2), p.W353 - W357

Trop, I., et al.

http://www.ajronline.org/content/197/2/W353.abstract?rss=1

The purpose of this article is to present the cases of four women who underwent percutaneous breast biopsy with deployment of a titanium metallic marker embedded in a bioresorbable collagen plug. Routine follow-up mammography after benign pathologic results were obtained revealed new fine microcalcifications at the biopsy sites, requiring repeat biopsy. Pathologic examination confirmed the presence of microcalcifications associated with an acidophilic foreign material.

Flat epithelial atypia of the breast: pathological-radiological correlation

Flat epithelial atypia of the breast: pathological-radiological correlation. AJR, Sept 2011, vol. 197(3), p. 740-746.

Solorzano, S., et al.

http://www.ajronline.org/content/197/3/740.abstract?rss=1

This study was undertaken to determine the prevalence of flat epithelial atypia at ultrasound-guided and stereotactically guided needle biopsies, to describe the mammographic and sonographic features of flat epithelial atypia, and to determine the significance of lesions diagnosed as flat epithelial atypia at imaging-guided needle biopsies.

Supplemental use of optical diffusion breast imaging for differentiation between benign and malignant breast lesions

Supplemental use of optical diffusion breast imaging for differentiation between benign and malignant breast lesions. AJR, Sept 2011, vol. 197(3), p. 732-739.

Moon, JH, et al.

http://www.ajronline.org/content/197/3/732.abstract?rss=1

The objective of this study was to prospectively evaluate the diagnostic accuracy of optical diffusion breast imaging in patients who underwent conventional ultrasound followed by surgery or biopsy.

Image guided preoperative hookwire localization of nonpalpable extramammory lesions

Image guided preoperative hookwire localization of nonpalpable extramammory lesions. AJR, Sept 2011, vol. 197(3), p. W525-W527

Kelan, KJ, et al.

http://www.ajronline.org/content/197/3/W525.abstract?rss=1

Imaging-guided hookwire localization of nonpalpable lesions in the breast is frequently performed preoperatively. Outside the breast, this procedure is useful for planning resection of lesions in anatomic regions without intrinsic landmarks. The purpose of this study was to review an experience with hookwire localization of nonpalpable extramammary lesions.

Management of uncommon chemotherapy-induced emergencies

Management of uncommon chemotherapy-induced emergencies. The Lancet Oncology, Aug 2011, vol. 12(8), p.806-814.

Morgan, C., et al.

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70208-4/abstract?rss=yes

Chemotherapy can induce various clinical emergencies. Prompt recognition and management of these adverse events are important for avoiding further morbidity and mortality.

Mastectomy and reconstruction in stage IV breast cancer

Mastectomy and reconstruction in stage IV breast cancer: A survery of UK breast and plastic surgeons. The Breast, Aug 2011, vol. 20(4), p.373-79.

Durrant, CAT, et al.

http://www.thebreastonline.com/article/PIIS0960977611000452/abstract?rss=yes

The number of women with stage IV disease who have breast reconstruction is small. The primary aim of this study was to examine opinions as to the appropriateness of breast reconstruction in this group.

Interest in cavity shaving in breast conservation treatment does not depend on lumpectomy technique

Interest in cavity shaving in breast conservation treatment does not depend on lumpectomy technique. The Breast, Aug 2011, vol. 20(4), p.358-64.

Feron, JG., et al.

http://www.thebreastonline.com/article/PIIS0960977611000300/abstract?rss=yes

In breast conserving surgery (BCS), the usefulness to perform systematic cavity shaving is actively debated. Some investigators argued that systematic cavity shaving could avoid surgical re-excision and make diagnosis of unexpected multifocality. Others argued that usefulness of cavity shaving depends on volumes of resection.

Optimal adjuvant therapy for very young breast cancer patients

Optimal adjuvant therapy for very young brest cancer patients. The Breast, Aug 2011, vol. 20(4), p.297-302.

Francis, PA.

http://www.thebreastonline.com/article/PIIS0960977611001032/abstract?rss=yes

Approximately one in forty women diagnosed with early breast cancer is very young (<35 years) and this age group has a worse prognosis. The inferior prognosis in very young women appears to have two aspects. Very young women present more frequently with tumors with adverse histo-pathologic features. However, even when the histo-pathologic features appear favorable (ie. endocrine responsive tumors), analyses suggest that very young women with hormone receptor positive tumors are a sub-group at particular risk for adverse outcomes, compared to older premenopausal women with similar tumors

How not to neglect the care of the elderly breast cancer patients

How not to neglect the care of the elderly breast cancer patient. The Breast, Aug 2011, vol. 20(4), p.293-96.

Tahir, M., et al.

http://www.thebreastonline.com/article/PIIS0960977611000907/abstract?rss=yes

Breast cancer is one of the leading causes of cancer mortality in women. Its incidence increases with increasing age; those over 70 years constitute more than one-third of the current breast cancer population. Despite significant advances in the field of breast cancer treatment, elderly patients have seen neither a meaningful improvement in treatment strategies, nor a decline in breast cancer-specific mortality.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer

Four year follow-up of trastuzumab plus adjuvant chemotherpy for operable HER2 positive breast cancer: Joint analysis of NNCTG N9831 and NSABP B-31. J Clin Oncol published online before print July 18, 2011

Wan, Y. (summary)

http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---July/19/Four-year-follow-up-of-trastuzumab-plus-adjuvant-chemotherapy-for-operable-HER2-positive-breast-cancer-Joint-analysis-of-NCCTG-N9831-and-NSABP-B-31/

Four large trials evaluating adjuvant trastuzumab for HER2-positive breast cancer demonstrated significant improvements in disease-free survival (DFS; 36% to 52% reduction in DFS events) and overall survival (OS; 33% to 37% reduction in deaths). These data has led adjuvant trastuzumab becoming the foundation of care for HER2-positive early breast cancer.

High-dose chemotherapy with stem-cell support gives no apparent survival benefit in breast cancer

High-dose chemotherapy with stem-cell support gives no apparent survival benefit in breast cancer. J Clin Oncol, published early online 18 July 2011

Glare, J. (summary)

http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---July/20/High-dose-chemotherapy-with-stem-cell-support-gives-no-apparent-survival-benefit-in-breast-cancer/

Two meta-analyses published early online by the Journal of Clinical Oncology examine the evidence on high-dose chemotherapy with stem-cell support in high-risk primary and in metastatic breast cancer: both found that while the technique produced small increases in relapse-free survival, it did not significantly prolong overall survival.

Triptorelin reduces risk of ovarian failure due to chemotherapy for breast cancer

Triptorelin reduces risk of ovarian failure due to chemotherapy for breast cancer. JAMA 2011; 306: 269-76

Glare, J. (summary)

http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---July/20/Triptorelin-reduces-risk-of-ovarian-failure-due-to-chemotherapy-for-breast-cancer/

Breast cancer in younger women is less common, about 12% aged under 45 years, but they are at increased risk of an adverse outcome and therefore most will receive intensive systemic chemotherapy. This may cause early ovarian failure leading to premature menopause: it is estimated that each month of chemotherapy translates into 1.5 years of lost reproductive life. There are no proven standard strategies for preventing this toxicity, however experimental work and pilot studies suggest that suppressing ovarian function with a gonadotropin-releasing hormone (GnRH) analogue might be helpful. This trial examined the hypothesis.